Measures for Conducting Comparative Benefit: Risk Assessment

In this article, we review quantitative measures that have been proposed to conduct comparative benefit:risk assessment. Comparative benefit:risk assessment could be conducted at the societal level (recommending drug approval or the adoption of a medical policy) or at the individual level (making a treatment selection). Benefit:risk assessment involves balancing between benefit and risk. The need to make decisions based on all information forces us to think diligently on the trade-off between benefit and risk in a structured manner. Even though we discuss measures to facilitate benefit:risk assessment in this article, we want to remind the readers that it cannot replace the rigorous assessment of efficacy and safety individually. Rather, it complements the traditionally separate safety and efficacy analysis by bringing safety and efficacy assessment together in a unified approach.

[1]  Stuart Walker,et al.  A quantitative approach to benefit-risk assessment of medicines - part 2: the practical application of a new model (vol 16, pg S16, 2007) , 2007 .

[2]  R. Gelber,et al.  Quality adjusted survival analysis. , 1990, Statistics in medicine.

[3]  H. Korting,et al.  The Benefit/Risk Ratio: A Handbook for the Rational Use of Potentially Hazardous Drugs , 1998 .

[4]  J. Hutton,et al.  Number needed to treat: properties and problems , 2000 .

[5]  M Pirmohamed,et al.  Current Assessment of Risk–Benefit by Regulators: Is It Time to Introduce Decision Analyses? , 2007, Clinical pharmacology and therapeutics.

[6]  R. Entsuah,et al.  Global Benefit-risk Evaluation of Antidepressant Action: Comparison of Pooled Data for Venlafaxine, SSRIs, and Placebo , 2002, CNS Spectrums.

[7]  C Chuang-Stein,et al.  Organization and analysis of safety data using a multivariate approach. , 1992, Statistics in medicine.

[8]  C Chuang-Stein,et al.  A new proposal for benefit-less-risk analysis in clinical trials. , 1994, Controlled clinical trials.

[9]  I. Bross How to use Ridit Analysis , 1958 .

[10]  Payne Jt,et al.  A survey of the benefits and risks in the practice of radiology. , 1975 .

[11]  Sam Salek,et al.  A quantitative approach to benefit‐risk assessment of medicines – part 1: the development of a new model using multi‐criteria decision analysis , 2007, Pharmacoepidemiology and drug safety.

[12]  J. Payne,et al.  A survey of the benefits and risks in the practice of radiology. , 1975, CRC critical reviews in clinical radiology and nuclear medicine.

[13]  Richard Entsuah,et al.  Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. , 2002, Journal of psychiatric research.

[14]  E Lesaffre,et al.  A note on the number needed to treat. , 1999, Controlled clinical trials.

[15]  S. Walter,et al.  Number needed to treat (NNT): estimation of a measure of clinical benefit , 2001, Statistics in medicine.

[16]  H. Mouridsen,et al.  Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Mary Cushman,et al.  Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[18]  J. Potter,et al.  Risks and benefits of celecoxib to prevent recurrent adenomas. , 2006, The New England journal of medicine.

[19]  Andrew P. Grieve,et al.  The number needed to treat: a useful clinical measure or a case of the Emperor's new clothes? , 2003 .

[20]  P. O'Brien Procedures for comparing samples with multiple endpoints. , 1984, Biometrics.

[21]  R. Temple Quantitative Decision Analysis: A Work in Progress , 2007, Clinical pharmacology and therapeutics.

[22]  H. Fineberg,et al.  Risk-Benefit Considerations in the Management of Polymyalgia Rheumatica , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.

[23]  Victor Kipnis,et al.  Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women's Health Initiative , 1996 .

[24]  Sam Salek,et al.  Retracted:A quantitative approach to benefit‐risk assessment of medicines — part 2: the practical application of a new model , 2007, Pharmacoepidemiology and drug safety.

[25]  V. Hasselblad,et al.  Placebo-Controls in Short-Term Clinical Trials of Hypertension , 2001, Science.

[26]  Richard D. Gelber,et al.  A quality-of-life-oriented endpoint for comparing therapies. , 1989 .

[27]  Ingram Olkin,et al.  Bias of estimates of the number needed to treat , 2005, Statistics in medicine.

[28]  C Chuang-Stein,et al.  Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. , 1991, Statistics in medicine.